DK2140867T4 - Farmaceutisk sammensætning - Google Patents
Farmaceutisk sammensætning Download PDFInfo
- Publication number
- DK2140867T4 DK2140867T4 DK08720658.7T DK08720658T DK2140867T4 DK 2140867 T4 DK2140867 T4 DK 2140867T4 DK 08720658 T DK08720658 T DK 08720658T DK 2140867 T4 DK2140867 T4 DK 2140867T4
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007087327 | 2007-03-29 | ||
PCT/JP2008/000791 WO2008129846A1 (ja) | 2007-03-29 | 2008-03-28 | 医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2140867T3 DK2140867T3 (da) | 2017-10-09 |
DK2140867T4 true DK2140867T4 (da) | 2023-09-25 |
Family
ID=39875378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08720658.7T DK2140867T4 (da) | 2007-03-29 | 2008-03-28 | Farmaceutisk sammensætning |
Country Status (28)
Country | Link |
---|---|
US (3) | US20100081685A1 (da) |
EP (1) | EP2140867B2 (da) |
JP (2) | JP4463875B2 (da) |
KR (1) | KR101424843B1 (da) |
CN (2) | CN101652139A (da) |
AU (1) | AU2008241982B2 (da) |
BR (1) | BRPI0809205B8 (da) |
CA (1) | CA2680039C (da) |
CO (1) | CO6220955A2 (da) |
CY (1) | CY1119377T1 (da) |
DK (1) | DK2140867T4 (da) |
ES (1) | ES2644803T5 (da) |
FI (1) | FI2140867T4 (da) |
HR (1) | HRP20171384T4 (da) |
HU (2) | HUE035990T2 (da) |
IL (2) | IL200790A (da) |
LT (2) | LT2140867T (da) |
MX (2) | MX2009010474A (da) |
MY (1) | MY149356A (da) |
NO (1) | NO20093008L (da) |
NZ (2) | NZ597109A (da) |
PL (1) | PL2140867T5 (da) |
PT (1) | PT2140867T (da) |
SG (1) | SG179497A1 (da) |
SI (1) | SI2140867T2 (da) |
TW (1) | TWI409064B (da) |
WO (1) | WO2008129846A1 (da) |
ZA (2) | ZA200906182B (da) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG179497A1 (en) | 2007-03-29 | 2012-04-27 | Daiichi Sankyo Co Ltd | Pharmaceutical composition |
SI2371830T1 (sl) | 2008-12-17 | 2014-01-31 | Daiichi Sankyo Company, Limited | Postopek za pridobivanje diaminskih derivatov |
EP2374456B1 (en) * | 2008-12-19 | 2016-08-03 | Daiichi Sankyo Company, Limited | Edoxaban dosage regime |
WO2010082531A1 (ja) | 2009-01-13 | 2010-07-22 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
JP5666424B2 (ja) | 2009-03-10 | 2015-02-12 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
EA201171329A1 (ru) * | 2009-04-30 | 2012-05-30 | Такеда Фармасьютикал Компани Лимитед | Твердый препарат |
ES2605034T3 (es) * | 2009-06-18 | 2017-03-10 | Daiichi Sankyo Company, Limited | Composición farmacéutica con solubilidad mejorada |
ES2706880T3 (es) | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
TW201132646A (en) * | 2010-02-22 | 2011-10-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
TW201200165A (en) * | 2010-02-22 | 2012-01-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
JP5390014B2 (ja) * | 2010-03-19 | 2014-01-15 | 第一三共株式会社 | 抗凝固剤の溶出改善方法 |
JP5692873B2 (ja) * | 2010-03-19 | 2015-04-01 | 第一三共株式会社 | ジアミン誘導体の結晶およびその製造方法 |
WO2012002538A1 (ja) * | 2010-07-02 | 2012-01-05 | 第一三共株式会社 | 光学活性ジアミン誘導体の塩の製造方法 |
US9402907B2 (en) | 2011-08-10 | 2016-08-02 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing diamine derivative |
WO2013026553A1 (en) | 2011-08-22 | 2013-02-28 | Ratiopharm Gmbh | Composition comprising edoxaban |
KR102127625B1 (ko) | 2012-09-03 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물 |
JP6227352B2 (ja) * | 2012-09-27 | 2017-11-08 | 株式会社三和化学研究所 | アナグリプチン又はその塩を含有する固形製剤 |
EP2952196A4 (en) * | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE |
TW201521794A (zh) * | 2013-11-12 | 2015-06-16 | Daiichi Sankyo Co Ltd | 錠劑 |
WO2015129603A1 (ja) * | 2014-02-25 | 2015-09-03 | 第一三共株式会社 | 活性化血液凝固第X因子(FXa)阻害剤の高純度結晶 |
US20170368037A1 (en) * | 2014-12-26 | 2017-12-28 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for promotion of fibrinolysis |
CN107405342B (zh) * | 2015-12-24 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有二胺衍生物或其盐的固体药物组合物 |
US20190364946A1 (en) * | 2016-03-16 | 2019-12-05 | Omegatri As | Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production |
JP6673798B2 (ja) * | 2016-10-12 | 2020-03-25 | 日本化薬株式会社 | カペシタビンを有効成分とするフィルムコート医薬製剤 |
TWI812602B (zh) | 2016-12-01 | 2023-08-21 | 日商第一三共股份有限公司 | 含二胺衍生物之口腔崩散錠及其製造方法 |
TWI826474B (zh) | 2018-06-27 | 2023-12-21 | 日商第一三共股份有限公司 | 包含二胺衍生物之顆粒劑、以及其用途及製造方法 |
KR102222774B1 (ko) * | 2018-07-27 | 2021-03-04 | 보령제약 주식회사 | 에독사반을 포함하는 약학적 제제 및 이의 제조방법 |
KR20200079957A (ko) | 2018-12-26 | 2020-07-06 | 한국콜마주식회사 | 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법 |
KR102514961B1 (ko) | 2019-03-05 | 2023-03-28 | 주식회사 파마코스텍 | 에독사반 벤젠술폰산염 1 수화물 결정형 및 그 제조방법 |
EP3744320A1 (en) | 2019-05-29 | 2020-12-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising edoxaban |
KR20210048632A (ko) | 2019-10-23 | 2021-05-04 | 한미약품 주식회사 | 에독사반 유리 염기 함유 제약 조성물 |
KR102333564B1 (ko) | 2019-11-28 | 2021-12-01 | 동방에프티엘(주) | 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로 |
KR102090912B1 (ko) | 2019-12-18 | 2020-03-18 | 유니셀랩 주식회사 | 신규한 결정형 형태의 에독사반 및 이의 제조방법 |
EP3838267A1 (en) | 2019-12-19 | 2021-06-23 | Biohorm, S.L. | Edoxaban tablets |
KR102513519B1 (ko) | 2020-06-08 | 2023-03-23 | 주식회사 파마코스텍 | 신규한 에독사반 벤젠술폰산염 1 수화물의 제조방법 |
KR102222784B1 (ko) | 2020-09-17 | 2021-03-04 | 유니셀랩 주식회사 | 신규한 에독사반 헤미에틸렌다이설퍼닉산 염 일수화물 |
EP4262760A1 (en) | 2020-12-18 | 2023-10-25 | KRKA, d.d., Novo mesto | Edoxaban formulation containing no sugar alcohols |
KR102518204B1 (ko) | 2022-02-18 | 2023-04-05 | 주식회사 엔비피헬스케어 | 신규한 에독사반 프로필렌글리콜 용매화물 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361545A (en) * | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
JP2814513B2 (ja) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | 溶出性の改良された製剤組成物 |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
US5149855A (en) | 1989-12-26 | 1992-09-22 | Mitsubishi Rayon Co., Ltd. | Process for racemizing optically active carboxylic acid esters |
US5055600A (en) | 1990-04-24 | 1991-10-08 | Rockwell International Corporation | Glycidyl azide polymer (gap) synthesis by molten salt method |
US5506248A (en) | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical preparations containing iftroban and methods for their preparation |
US5677469A (en) | 1995-05-18 | 1997-10-14 | Sepracor, Inc. | Process for resolving chiral acids with 1-aminoindan-2-ols |
JPH09309829A (ja) * | 1996-05-22 | 1997-12-02 | Taiyo Yakuhin Kogyo Kk | ニトレンジピン含有経口投与製剤およびその製造法 |
US5958453A (en) * | 1996-10-31 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
JPH11180899A (ja) | 1997-12-15 | 1999-07-06 | Mitsui Chem Inc | 活性メチレンアルキル化化合物の製造法 |
JP3680203B2 (ja) | 1999-06-01 | 2005-08-10 | 東洋化成工業株式会社 | 4−アセチルアミノベンゼンスルホニルアジドの製造方法 |
JP4044709B2 (ja) * | 1999-11-19 | 2008-02-06 | 信越化学工業株式会社 | 水系フィルムコーティング剤及び経口固形製剤 |
JP2001151724A (ja) | 1999-11-19 | 2001-06-05 | Kuraray Co Ltd | 光学活性な2,2,4−トリメチル−3−シクロヘキセンカルボン酸の製造方法 |
TWI288745B (en) | 2000-04-05 | 2007-10-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
RU2271805C2 (ru) | 2000-10-24 | 2006-03-20 | Адзиномото Ко., Инк. | Препарат, содержащий натеглинид |
DE10106971A1 (de) * | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharma | Arzneimittelformulierung die einen muskarinischen Agonisten enthält |
US20020160048A1 (en) * | 2001-02-15 | 2002-10-31 | Karoline Bechtold-Peters | Medical formulation containing a muscarinic agonist |
KR100908418B1 (ko) * | 2001-06-20 | 2009-07-21 | 액티버스 파마 컴퍼니 리미티드 | 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법 |
JP3939601B2 (ja) * | 2001-06-20 | 2007-07-04 | 株式会社アクティバスファーマ | キノリノン誘導体医薬組成物及びその製造方法 |
EP1405852B9 (en) | 2001-06-20 | 2013-03-27 | Daiichi Sankyo Company, Limited | Diamine derivatives |
US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
ES2383749T3 (es) | 2001-08-09 | 2012-06-26 | Daiichi Sankyo Company, Limited | Derivados de diamina |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
TW200306868A (en) * | 2002-05-22 | 2003-12-01 | Shionogi & Co | Composition of hardly soluble medicine with improved solubility |
JP4109288B2 (ja) | 2002-12-25 | 2008-07-02 | 第一三共株式会社 | ジアミン誘導体 |
PE20131352A1 (es) * | 2003-04-08 | 2013-11-14 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
KR101060885B1 (ko) * | 2003-06-17 | 2011-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 염산 베니디핀 함유 의약 조성물 |
JP4606258B2 (ja) * | 2003-06-17 | 2011-01-05 | 協和発酵キリン株式会社 | 塩酸ベニジピン含有医薬組成物 |
JP4759388B2 (ja) | 2003-11-12 | 2011-08-31 | 第一三共株式会社 | チアゾール誘導体の製造法 |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
US8686189B2 (en) | 2005-09-16 | 2014-04-01 | Daiichi Sankyo Company, Limited | Optically active diamine derivative and process for producing the same |
JP4703333B2 (ja) | 2005-09-26 | 2011-06-15 | エヌ・ティ・ティ・ソフトウェア株式会社 | 電子メール処理プログラム |
SG179497A1 (en) | 2007-03-29 | 2012-04-27 | Daiichi Sankyo Co Ltd | Pharmaceutical composition |
TW200909437A (en) | 2007-06-21 | 2009-03-01 | Daiichi Sankyo Co Ltd | Process for the preparation of diamine-derivatives |
EP2368870A1 (en) | 2008-12-12 | 2011-09-28 | Daiichi Sankyo Company, Limited | Process for producing optically active carboxylic acid |
SI2371830T1 (sl) | 2008-12-17 | 2014-01-31 | Daiichi Sankyo Company, Limited | Postopek za pridobivanje diaminskih derivatov |
EP2374456B1 (en) | 2008-12-19 | 2016-08-03 | Daiichi Sankyo Company, Limited | Edoxaban dosage regime |
WO2010082531A1 (ja) | 2009-01-13 | 2010-07-22 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
JP5666424B2 (ja) | 2009-03-10 | 2015-02-12 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
WO2010131663A1 (ja) | 2009-05-15 | 2010-11-18 | 第一三共株式会社 | オキサミド誘導体 |
ES2605034T3 (es) | 2009-06-18 | 2017-03-10 | Daiichi Sankyo Company, Limited | Composición farmacéutica con solubilidad mejorada |
JP2011051672A (ja) | 2009-08-31 | 2011-03-17 | Ihi Corp | ラック棚及びラック棚の組立て方法 |
JP5692873B2 (ja) | 2010-03-19 | 2015-04-01 | 第一三共株式会社 | ジアミン誘導体の結晶およびその製造方法 |
US20130158069A1 (en) | 2011-12-14 | 2013-06-20 | Daiichi Sankyo Company, Limited | Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment |
-
2008
- 2008-03-28 SG SG2012018826A patent/SG179497A1/en unknown
- 2008-03-28 HU HUE08720658A patent/HUE035990T2/en unknown
- 2008-03-28 DK DK08720658.7T patent/DK2140867T4/da active
- 2008-03-28 KR KR1020097019320A patent/KR101424843B1/ko active Protection Beyond IP Right Term
- 2008-03-28 AU AU2008241982A patent/AU2008241982B2/en active Active
- 2008-03-28 MX MX2009010474A patent/MX2009010474A/es active IP Right Grant
- 2008-03-28 HR HRP20171384TT patent/HRP20171384T4/hr unknown
- 2008-03-28 EP EP08720658.7A patent/EP2140867B2/en active Active
- 2008-03-28 CN CN200880010935A patent/CN101652139A/zh active Pending
- 2008-03-28 CN CN201410468293.6A patent/CN104324015B/zh active Active
- 2008-03-28 WO PCT/JP2008/000791 patent/WO2008129846A1/ja active Application Filing
- 2008-03-28 JP JP2009510780A patent/JP4463875B2/ja active Active
- 2008-03-28 LT LTEP08720658.7T patent/LT2140867T/lt unknown
- 2008-03-28 CA CA2680039A patent/CA2680039C/en active Active
- 2008-03-28 NZ NZ59710908A patent/NZ597109A/xx unknown
- 2008-03-28 FI FIEP08720658.7T patent/FI2140867T4/fi active
- 2008-03-28 TW TW97111503A patent/TWI409064B/zh active
- 2008-03-28 MX MX2011010260A patent/MX351987B/es unknown
- 2008-03-28 BR BRPI0809205A patent/BRPI0809205B8/pt active IP Right Grant
- 2008-03-28 SI SI200831863T patent/SI2140867T2/sl unknown
- 2008-03-28 PT PT87206587T patent/PT2140867T/pt unknown
- 2008-03-28 NZ NZ579725A patent/NZ579725A/en unknown
- 2008-03-28 MY MYPI20093689 patent/MY149356A/en unknown
- 2008-03-28 PL PL08720658.7T patent/PL2140867T5/pl unknown
- 2008-03-28 ES ES08720658T patent/ES2644803T5/es active Active
-
2009
- 2009-09-07 IL IL200790A patent/IL200790A/en not_active IP Right Cessation
- 2009-09-07 ZA ZA2009/06182A patent/ZA200906182B/en unknown
- 2009-09-16 NO NO20093008A patent/NO20093008L/no unknown
- 2009-09-28 CO CO09106060A patent/CO6220955A2/es not_active Application Discontinuation
- 2009-09-29 US US12/569,057 patent/US20100081685A1/en not_active Abandoned
-
2010
- 2010-01-18 JP JP2010007969A patent/JP2010090168A/ja active Pending
- 2010-08-18 ZA ZA2010/05906A patent/ZA201005906B/en unknown
-
2012
- 2012-05-16 IL IL219829A patent/IL219829A0/en unknown
-
2013
- 2013-08-16 US US13/968,776 patent/US9149532B2/en active Active
-
2015
- 2015-08-12 US US14/825,036 patent/US9707296B2/en active Active
-
2017
- 2017-09-20 CY CY20171100990T patent/CY1119377T1/el unknown
-
2018
- 2018-01-25 LT LTPA2018005C patent/LTC2140867I2/lt unknown
- 2018-02-12 HU HUS1800007C patent/HUS1800007I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2140867I2 (lt) | Farmacinė kompozicija | |
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
RU2493831C3 (ru) | Фармацевтические композиции | |
BRPI0719393A2 (pt) | Composição farmacêutica | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
BRPI0820381A2 (pt) | Formulações farmacêuticas | |
BRPI0813775A2 (pt) | Composição | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
DK2041139T3 (da) | Farmaceutiske forbindelser | |
ATE528048T1 (de) | Schweisshemmende/desodorierende zusammensetzung | |
BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
BRPI0720234A2 (pt) | Composição farmacêutica | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
BRPI0810557A2 (pt) | composição | |
BRPI0811274A2 (pt) | Composição | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
BRPI0817833A2 (pt) | Composição farmacêutica antimalárica | |
BRPI0820198A2 (pt) | composições farmacêuticas | |
DK2966175T3 (da) | Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat | |
DK2271618T3 (da) | Farmaceutiske forbindelser | |
BRPI0811002A2 (pt) | Composição biofertilizante | |
BRPI0912171A2 (pt) | composição farmacêutica | |
BRPI0820960A2 (pt) | composição |